Skip to content

Study · Non-randomized trial · n = 14 · 2006

10 results

Oral salmon calcitonin reduces Lequesne's algofunctional index scores and decreases urinary and serum levels of biomarkers of joint metabolism in knee osteoarthritis.

Manicourt DH, Azria M, Mindeholm L, Thonar EJ, Devogelaer JP

Arthritis and rheumatism1 Oct 2006Cited by 97 (Europe PMC)

PMID17009253 (opens in a new tab)DOI10.1002/art.22075 (opens in a new tab)PepBankPUB-17009253
Publisher pagePubMedAsk about this study
Jump to 10 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study10

10 results from studies that gave the peptide. 10 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In knee osteoarthritis, pain scores decreased significantly with salmon calcitonin, with a similar decrease in the placebo group on day 84.

    In plain wordsIn patients with knee osteoarthritis, pain decreased during salmon calcitonin treatment, with a similar decrease during placebo treatment.

    Peptide
    Calcitonin-salmon
    Outcome
    DecreasePain score
    Study

    n = 14

    Comparator
    Baseline
    Outcome group
    Pain · Musculoskeletal
    Studied dose
    1 mg daily · oral · 84 daysAs given in this study (human).

    Source sentences

    Summary
    Although, on day 84, patients in both the placebo group and the group receiving 1 mg of sCT exhibited a similar significant decrease in pain scores, a significant reduction in the function score was observed only in the 2 sCT groups.
    1 context sentence
    Summary · context
    In this randomized, double-blind trial, patients received either placebo (n = 18), 0.5 mg of sCT (n = 17), or 1 mg of sCT (n = 18) daily for 84 days.
  2. 02HumanNon-randomized trialEfficacy outcome

    In patients with knee osteoarthritis, function scores decreased significantly from baseline with salmon calcitonin on day 84.

    In plain wordsIn patients with knee osteoarthritis, function scores decreased significantly from baseline with salmon calcitonin.

    Peptide
    Calcitonin-salmon
    Outcome
    DecreaseFunction score
    Study

    n = 14

    Comparator
    Baseline
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    1 mg daily · oral · 84 daysAs given in this study (human).

    Source sentences

    Summary
    Although, on day 84, patients in both the placebo group and the group receiving 1 mg of sCT exhibited a similar significant decrease in pain scores, a significant reduction in the function score was observed only in the 2 sCT groups.
    1 context sentence
    Summary · context
    In this randomized, double-blind trial, patients received either placebo (n = 18), 0.5 mg of sCT (n = 17), or 1 mg of sCT (n = 18) daily for 84 days.
  3. 03HumanNon-randomized trialEfficacy outcome

    In patients with knee osteoarthritis, salmon calcitonin significantly reduced MMP-3 from baseline on day 84.

    In plain wordsIn patients with knee osteoarthritis, salmon calcitonin reduced MMP-3 from baseline.

    Peptide
    Calcitonin-salmon
    Outcome
    DecreaseMMP-3
    Study

    n = 14

    Comparator
    Baseline
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    1 mg daily · oral · 84 daysAs given in this study (human).

    Source sentences

    Summary
    On day 84, there was no significant decrease in biomarker levels in the placebo group, whereas significant reductions in the levels of both MMP-3 and hyaluronan were observed in the 2 sCT groups.
    1 context sentence
    Summary · context
    In this randomized, double-blind trial, patients received either placebo (n = 18), 0.5 mg of sCT (n = 17), or 1 mg of sCT (n = 18) daily for 84 days.
  4. 04HumanNon-randomized trialEfficacy outcome

    In patients with knee osteoarthritis, salmon calcitonin significantly reduced hyaluronan from baseline on day 84.

    In plain wordsIn patients with knee osteoarthritis, salmon calcitonin reduced hyaluronan from baseline.

    Peptide
    Calcitonin-salmon
    Outcome
    DecreaseHyaluronan
    Study

    n = 14

    Comparator
    Baseline
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    1 mg daily · oral · 84 daysAs given in this study (human).

    Source sentences

    Summary
    On day 84, there was no significant decrease in biomarker levels in the placebo group, whereas significant reductions in the levels of both MMP-3 and hyaluronan were observed in the 2 sCT groups.
    1 context sentence
    Summary · context
    In this randomized, double-blind trial, patients received either placebo (n = 18), 0.5 mg of sCT (n = 17), or 1 mg of sCT (n = 18) daily for 84 days.
  5. 05HumanNon-randomized trialEfficacy outcome

    In patients with knee osteoarthritis, salmon calcitonin significantly reduced CTX-II from baseline.

    In plain wordsIn patients with knee osteoarthritis, salmon calcitonin reduced CTX-II from baseline.

    Peptide
    Calcitonin-salmon
    Outcome
    DecreaseCTX-II
    Study

    n = 14

    Comparator
    Baseline
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    1 mg daily · oral · 84 daysAs given in this study (human).

    Source sentences

    Summary
    The group of patients receiving 1 mg of sCT exhibited significant decreases in the levels of CTX-II, C2C, and MMP-13.
    1 context sentence
    Summary · context
    In this randomized, double-blind trial, patients received either placebo (n = 18), 0.5 mg of sCT (n = 17), or 1 mg of sCT (n = 18) daily for 84 days.
  6. 06HumanNon-randomized trialEfficacy outcome

    In patients with knee osteoarthritis, salmon calcitonin significantly reduced C2C from baseline.

    In plain wordsIn patients with knee osteoarthritis, salmon calcitonin reduced C2C from baseline.

    Peptide
    Calcitonin-salmon
    Outcome
    DecreaseC2C
    Study

    n = 14

    Comparator
    Baseline
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    1 mg daily · oral · 84 daysAs given in this study (human).

    Source sentences

    Summary
    The group of patients receiving 1 mg of sCT exhibited significant decreases in the levels of CTX-II, C2C, and MMP-13.
    1 context sentence
    Summary · context
    In this randomized, double-blind trial, patients received either placebo (n = 18), 0.5 mg of sCT (n = 17), or 1 mg of sCT (n = 18) daily for 84 days.
  7. 07HumanNon-randomized trialEfficacy outcome

    In patients with knee osteoarthritis, salmon calcitonin significantly reduced MMP-13 from baseline.

    In plain wordsIn patients with knee osteoarthritis, salmon calcitonin reduced MMP-13 from baseline.

    Peptide
    Calcitonin-salmon
    Outcome
    DecreaseMMP-13
    Study

    n = 14

    Comparator
    Baseline
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    1 mg daily · oral · 84 daysAs given in this study (human).

    Source sentences

    Summary
    The group of patients receiving 1 mg of sCT exhibited significant decreases in the levels of CTX-II, C2C, and MMP-13.
    1 context sentence
    Summary · context
    In this randomized, double-blind trial, patients received either placebo (n = 18), 0.5 mg of sCT (n = 17), or 1 mg of sCT (n = 18) daily for 84 days.
  8. 08HumanNon-randomized trialEfficacy outcome

    In patients with knee osteoarthritis, function scores decreased significantly from baseline with salmon calcitonin on day 84.

    In plain wordsIn patients with knee osteoarthritis, function scores decreased significantly from baseline with salmon calcitonin.

    Peptide
    Calcitonin-salmon
    Outcome
    DecreaseFunction score
    Study

    n = 13

    Comparator
    Baseline
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    0.5 mg daily · oral · 84 daysAs given in this study (human).

    Source sentences

    Summary
    Although, on day 84, patients in both the placebo group and the group receiving 1 mg of sCT exhibited a similar significant decrease in pain scores, a significant reduction in the function score was observed only in the 2 sCT groups.
    1 context sentence
    Summary · context
    In this randomized, double-blind trial, patients received either placebo (n = 18), 0.5 mg of sCT (n = 17), or 1 mg of sCT (n = 18) daily for 84 days.
  9. 09HumanNon-randomized trialEfficacy outcome

    In patients with knee osteoarthritis, salmon calcitonin significantly reduced MMP-3 from baseline on day 84.

    In plain wordsIn patients with knee osteoarthritis, salmon calcitonin reduced MMP-3 from baseline.

    Peptide
    Calcitonin-salmon
    Outcome
    DecreaseMMP-3
    Study

    n = 13

    Comparator
    Baseline
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    0.5 mg daily · oral · 84 daysAs given in this study (human).

    Source sentences

    Summary
    On day 84, there was no significant decrease in biomarker levels in the placebo group, whereas significant reductions in the levels of both MMP-3 and hyaluronan were observed in the 2 sCT groups.
    1 context sentence
    Summary · context
    In this randomized, double-blind trial, patients received either placebo (n = 18), 0.5 mg of sCT (n = 17), or 1 mg of sCT (n = 18) daily for 84 days.
  10. 10HumanNon-randomized trialEfficacy outcome

    In patients with knee osteoarthritis, salmon calcitonin significantly reduced hyaluronan from baseline on day 84.

    In plain wordsIn patients with knee osteoarthritis, salmon calcitonin reduced hyaluronan from baseline.

    Peptide
    Calcitonin-salmon
    Outcome
    DecreaseHyaluronan
    Study

    n = 13

    Comparator
    Baseline
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    0.5 mg daily · oral · 84 daysAs given in this study (human).

    Source sentences

    Summary
    On day 84, there was no significant decrease in biomarker levels in the placebo group, whereas significant reductions in the levels of both MMP-3 and hyaluronan were observed in the 2 sCT groups.
    1 context sentence
    Summary · context
    In this randomized, double-blind trial, patients received either placebo (n = 18), 0.5 mg of sCT (n = 17), or 1 mg of sCT (n = 18) daily for 84 days.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.